Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trialDouglas R. Adkins, Makoto Tahara, Jin-Ching Lin et al.|Oral Oncology|2021Cited by 43
ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical TrialsHillary S. Andrews, Jeff Allen, Shibing Deng et al.|Clinical Cancer Research|2025Cited by 19
Data from ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical TrialsHillary S. Andrews, Jeff Allen, Névine Zariffa et al.|Unknown|2025Cited by 0
Supplementary Table S1 from ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical TrialsHillary S. Andrews, Jeff Allen, Névine Zariffa et al.|Unknown|2025Cited by 0
Supplementary Figure S5 from ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical TrialsHillary S. Andrews, Jeff Allen, Névine Zariffa et al.|Unknown|2025Cited by 0